Indeed, we confirmed that treatment with rituximab significantly inhibited the expression of both STAT3-PS727 and STAT3-PY705, and secretion of IL-10 in a panel of DLBCL cell lines. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.